4.235
price down icon0.59%   -0.025
 
loading
Precedente Chiudi:
$4.26
Aprire:
$4.16
Volume 24 ore:
86,477
Relative Volume:
0.60
Capitalizzazione di mercato:
$45.67M
Reddito:
-
Utile/perdita netta:
$-19.09M
Rapporto P/E:
-2.3792
EPS:
-1.78
Flusso di cassa netto:
$-17.24M
1 W Prestazione:
+6.14%
1M Prestazione:
+36.17%
6M Prestazione:
-21.57%
1 anno Prestazione:
-6.72%
Intervallo 1D:
Value
$4.1001
$4.34
Intervallo di 1 settimana:
Value
$3.55
$4.41
Portata 52W:
Value
$2.55
$6.118

Lantern Pharma Inc Stock (LTRN) Company Profile

Name
Nome
Lantern Pharma Inc
Name
Telefono
972-277-1136
Name
Indirizzo
1920 MCKINNEY AVENUE, DALLAS, TX
Name
Dipendente
24
Name
Cinguettio
@lanternpharma
Name
Prossima data di guadagno
2025-03-21
Name
Ultimi documenti SEC
Name
LTRN's Discussions on Twitter

Confronta LTRN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
LTRN
Lantern Pharma Inc
4.235 45.94M 0 -19.09M -17.24M -1.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-10-07 Iniziato H.C. Wainwright Buy

Lantern Pharma Inc Borsa (LTRN) Ultime notizie

pulisher
05:23 AM

Is Lantern Pharma Inc. Stock Overbought or Oversold RSI Indicator AnalysisHigh Potential Safe Trades - Newser

05:23 AM
pulisher
Jul 26, 2025

Why Lantern Pharma Inc. stock attracts strong analyst attentionFree Professional Portfolio Management - Metal.it

Jul 26, 2025
pulisher
Jul 26, 2025

Lantern Pharma secures EU patent for AI-driven cancer drug LP-284 - MSN

Jul 26, 2025
pulisher
Jul 25, 2025

What analysts say about Lantern Pharma Inc. stockRapid growth opportunities - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Bellingham Herald

Jul 25, 2025
pulisher
Jul 25, 2025

Is Lantern Pharma Inc. a good long term investmentFree Stock Market Real-Time Monitoring - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

Will Lantern Pharma Inc. stock benefit from interest rate changesExceptional gains - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

How Lantern Pharma Inc. stock performs during market volatilityBalanced Risk Reward Portfolio - Newser

Jul 24, 2025
pulisher
Jul 24, 2025

Why Lantern Pharma Inc. stock is on top investor watchlistsOverwhelming financial success - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Lantern Pharma Inc. Stock Analysis and ForecastBreakthrough stock performance - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

What drives Lantern Pharma Inc. stock priceTremendous gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Lantern Pharma (NASDAQ: LTRN) Reports First Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL - Barchart.com

Jul 23, 2025
pulisher
Jul 23, 2025

Lantern Pharma reports complete response in aggressive lymphoma patient - Investing.com Australia

Jul 23, 2025
pulisher
Jul 23, 2025

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial - Business Wire

Jul 23, 2025
pulisher
Jul 22, 2025

Lantern Pharma (NASDAQ: LTRN) Secures EU Patent For AI-Designed Cancer Drug LP-284 - Barchart.com

Jul 22, 2025
pulisher
Jul 22, 2025

Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284 - The Globe and Mail

Jul 22, 2025
pulisher
Jul 21, 2025

Lantern Pharma (LTRN) Secures EU Patent for Cancer Drug LP-284 - GuruFocus

Jul 21, 2025
pulisher
Jul 21, 2025

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy - BioSpace

Jul 21, 2025
pulisher
Jul 21, 2025

Lantern Pharma (LTRN) Gains Patent Approval for Key Drug in Euro - GuruFocus

Jul 21, 2025
pulisher
Jul 17, 2025

Lantern Pharma Unveils AI Module for Predicting Cancer Treatment Efficacy - AInvest

Jul 17, 2025
pulisher
Jul 16, 2025

Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

IBN Initiates Coverage of Lantern Pharma Inc. - GlobeNewswire

Jul 16, 2025
pulisher
Jul 16, 2025

Lantern Pharma Initiates Coverage with IBN, Aims to Revolutionize Oncology Drug Development - AInvest

Jul 16, 2025

Lantern Pharma Inc Azioni (LTRN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Lantern Pharma Inc Azioni (LTRN) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Kreis Leslie W.
10% Owner
Jun 13 '25
Sale
3.09
40,000
123,600
49,957
Fletcher Aaron G.L.
10% Owner
Jun 12 '25
Sale
3.38
60,647
204,987
51,860
Fletcher Aaron G.L.
10% Owner
Jun 11 '25
Sale
3.40
950
3,230
54,746
Fletcher Aaron G.L.
10% Owner
Jun 10 '25
Sale
3.40
16
54
54,791
Kreis Leslie W.
10% Owner
Jun 12 '25
Sale
3.38
60,647
204,987
51,860
Kreis Leslie W.
10% Owner
Jun 11 '25
Sale
3.40
950
3,230
54,746
Kreis Leslie W.
10% Owner
Jun 10 '25
Sale
3.40
16
54
54,791
Fletcher Aaron G.L.
10% Owner
May 27 '25
Sale
3.05
21,037
64,163
56,467
Fletcher Aaron G.L.
10% Owner
May 29 '25
Sale
3.03
20,200
61,206
54,792
Fletcher Aaron G.L.
10% Owner
May 28 '25
Sale
2.87
15,000
43,050
55,753
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Capitalizzazione:     |  Volume (24 ore):